Constructed using low-drug-absorbing plastics, Chip-R1 builds upon the core microfluidic design of Organ-Chips, offering researchers greater precision in predicting human drug responses.
A trial is recruiting patients to test the gene-editing technology’s ability to treat an inherited form of blindness caused by a mutation in the CEP290 gene.